samedan logo
home > pmps > winter 2021 > vaccine logistics: deep-freeze storage in container design
Pharmaceutical Manufacturing and Packing Sourcer

Vaccine Logistics: Deep-Freeze Storage in Container Design

How Do You Transport and Store Vaccines Reliably at Temperatures of -70°C to -80°C?

L&R Kältetechnik has developed a coherent, efficient, and innovative concept for this challenge: a deepfreeze storage system that is installed in an industrial container. The basis for the development is the comprehensive knowledge L&R has acquired for the planning and manufacturing of sophisticated (deep) freeze systems and ultra-low temperature storage systems for pharmaceutical production.

Originally, the ‘core business’ for L&R Kältetechnik in the pharma industry was to provide the low temperatures required for production. Many production sites all over Europe are equipped with L&R cooling systems that can reach a cooling capacity in the megawatt (MW) range, and are absolutely fail-safe thanks to redundant refrigerating circuits.

Process Cooling For Pharma Production – Even in a Multi-Megawatt Range

One current example: L&R planned and installed a large cooling facility providing low temperatures on two levels of -15°C and -25°C for a manufacturer of medicines for the treatment of blood diseases such as haemophilia – and on a large scale at that. A total of five ultra-low temperature systems with 12 refrigerating circuits and a total cooling capacity of 2.35MW generate the required process cooling.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

L&R Kältetechnik GmbH & Co.

KG Hachenerstrasse 90a-c 59846 Sundern


Read more on L&R’s mobile pharma storage: https://bit. ly/3adrqfN
Print this page
Send to a friend
Privacy statement
News and Press Releases

Actimed Therapeutics Secures Significant New Patent, Extending IP Coverage of its Lead Compound for Use in Key Indication

London, UK – 4 May 2022: Actimed Therapeutics Ltd, a clinical stage company focused on bringing innovation to the treatment of muscle wasting disorders, today announced the grant of a new UK Patent (GB 2593902 B) covering new salts of S-pindolol for use in the treatment or prevention of cachexia with an expiry date in 2040. An international patent application has also been filed under the Patent Cooperation Treaty (PCT) and was published in October 2021, which seeks to extend patent protection for new S-pindolol salts to all relevant major international markets out to 2041.
More info >>

White Papers

High Containment FIBCs Offer a Safe and Cost Effective Alternative to their Rigid Counterparts

ILC Dover

As the need for powder containment and manufacturing in accordance with cGMP standards has grown over the years, companies have sought new alternatives to rigid IBCs. Recently high containment Flexible Intermediate Bulk Containers (FIBCs) have emerged which offer an alternative that provides both powder containment and the benefits of shipping with flexibles.
More info >>




©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement